Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2

Conditions

Neuroendocrine Tumors 35Carcinoma, Neuroendocrine 10Carcinoid Tumor 10Neoplasms 6Adenoma, Islet Cell 6Carcinoma, Renal Cell 5Carcinoma, Islet Cell 5Somatostatinoma 4Pheochromocytoma 4Insulinoma 4Glucagonoma 4Carcinoma, Medullary 4Paraganglioma 3Neoplasm Metastasis 3Gastrinoma 3Carcinoma 3Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Neuroectodermal Tumors, Primitive 2Liver Neoplasms 2Head and Neck Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Merkel Cell 2Carcinoma, Hepatocellular 2Adenocarcinoma, Follicular 2von Hippel-Lindau Disease 1Zollinger-Ellison Syndrome 1Tuberous Sclerosis 1

Interventions

Everolimus 2trifluridine tipiracil drug combination 1surufatinib 1pegfilgrastim 1pasireotide 1gallium Ga 68 dotatate 1fosbretabulin 1entinostat 1dactolisib 1belzutifan 1Temozolomide 1TH 302 1Surveys and Questionnaires 1Sunitinib 1Photochemotherapy 1Nivolumab 1Filgrastim 1Fentanyl 1Dihematoporphyrin Ether 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive × Everolimus × Endocrine × Clear all
NCT01374451 2016-12-20

COOPERATE-2

Novartis

Phase 2 Terminated
160 enrolled 17 charts
EndocrineNET

Adenoma, Islet Cell, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT01628913 2016-04-07

Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

Novartis

Phase 2 Terminated
62 enrolled 7 charts
EndocrineNET

Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡